Pasotuxizumab, CAS 1442657-12-6

Product Description: Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2019 37:15_suppl, 5034-5034. /[2]Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012 Dec;11(12):2664-73.

CAS Number: 1442657-12-6

Molecular Weight: N/A

Compound Purity: 98.02

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CD3

• Artikelnummer: MEXHY-P99802-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99802-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated